Related Experiment Video
Updated: Jun 16, 2025
Contrast Ultrasound Targeted Treatment of Gliomas in Mice via Drug-Bearing Nanoparticle Delivery and Microvascular Ablation
Published on: December 15, 2010
Targeting GLI1 and BAX by nanonoscapine could impede prostate adenocarcinoma progression
Mohammad Hossein Derakhshan Nazari1, Ronak Heidarian2, Mina Masoudnia3
1Department of Microbiology and Microbial Biotechnology, Faculty of Life Science and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Abstract:
Prostate cancer as a critical global health issue, requires the exploration of a novel therapeutic approach. Noscapine, an opium-derived phthalide isoquinoline alkaloid, has shown promise in cancer treatment thanks to its anti-tumorigenic properties. However, limitations such as low bioavailability and potential side effects have hindered its clinical application. This study introduces nanonoscapine as a novel medication to overcome these challenges, leveraging the advantages of improved drug delivery and efficacy achieved in nanotechnology. We monitored the effects of nanonoscapine on the androgen-sensitive human prostate adenocarcinoma cell line, LNCaP, investigating its impact on GLI1 and BAX genes' expressions, crucial regulators of cell cycle and apoptosis. Our findings, from MTT assays, flow cytometry, and gene expression analyses, have demonstrated that nanonoscapine effectively inhibits prostate cancer cell proliferation by inducing G2/M phase arrest and apoptosis. Furthermore, through bioinformatics and computational analyses, we have revealed the underlying molecular mechanisms, underscoring the therapeutic potential of nanonoscapine in enhancing patient outcomes. This study highlights the significance of nanonoscapine as an alternative or adjunct treatment to conventional chemotherapy, warranting further investigation in clinical settings.
Insights
Nanonoscapine effectively inhibits prostate cancer cell proliferation by inducing apoptosis and cell cycle arrest. This novel nanotechnology approach shows promise for improved cancer treatment outcomes.
Area of Science:
- Oncology
- Nanotechnology
- Pharmacology
Background:
- Prostate cancer is a major global health concern requiring new treatments.
- Noscapine, an opium alkaloid, has anti-tumor properties but suffers from low bioavailability and side effects.
- Nanotechnology offers potential solutions for drug delivery challenges in cancer therapy.
Purpose of the Study:
- To introduce nanonoscapine as a novel therapeutic agent for prostate cancer.
- To evaluate the effects of nanonoscapine on prostate cancer cell proliferation and apoptosis.
- To elucidate the molecular mechanisms underlying nanonoscapine's anti-cancer activity.
Main Methods:
- Utilized the androgen-sensitive LNCaP prostate cancer cell line.
- Performed MTT assays, flow cytometry, and gene expression analyses (GLI1, BAX).
- Conducted bioinformatics and computational analyses to understand molecular mechanisms.
Main Results:
- Nanonoscapine significantly inhibited prostate cancer cell proliferation.
- Induction of G2/M phase arrest and apoptosis was observed.
- Key gene expressions related to cell cycle and apoptosis were modulated.
Conclusions:
- Nanonoscapine demonstrates significant anti-prostate cancer effects by inducing cell cycle arrest and apoptosis.
- The study reveals the molecular mechanisms, highlighting nanonoscapine's therapeutic potential.
- Nanonoscapine represents a promising alternative or adjunct treatment for prostate cancer, meriting clinical investigation.
